share_log

Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5

Benzinga ·  Dec 16, 2024 07:29  · Ratings

Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers the price target from $7 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment